Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) Meeting Abstract
| Authors: | Lau, G.; Cheng, A. L.; Sangro, B.; Kudo, M.; Kelley, R. K.; Tak, W. Y.; Gasbarrini, A.; Reig, M.; Lim, H. Y.; Tougeron, D.; De Toni, E. N.; Tam, V. C.; Mody, K.; Gong, J.; McCoy, C. L.; Gupta, C.; Makowsky, M.; Negro, A.; Abou-Alfa, G. K. |
| Abstract Title: | Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.4004 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4004 -- This meeting was also held virtually -- Source: Cinahl |
